This educational activity expands general practitioners’ knowledge and clinical confidence in identifying and managing patients with severe asthma, particularly those with Type 2 inflammation who remain symptomatic despite optimised inhaled therapy.
The session explores the pathophysiology of severe asthma, biomarkers of Type 2 inflammation, and the role of biologic therapies in achieving better symptom control and reducing exacerbations. Participants will learn how to review existing patients, identify those who may qualify for advanced therapy, and collaborate with local respiratory physicians for specialist assessment and treatment initiation.
By understanding the referral pathways and evidence supporting biologic use, GPs can enhance continuity of care, improve patient outcomes, and offer access to cutting-edge therapies for those with difficult-to-control asthma.
By completing this activity, participants will be able to:
-
Recognise the clinical features and diagnostic criteria of severe asthma and Type 2 inflammation.
-
Differentiate between mild-to-moderate asthma and cases that warrant escalation to advanced therapies.
-
Apply evidence-based assessment tools to identify patients not controlled on standard inhaled treatments.
-
Refer appropriately to local respiratory physicians for consideration of biologic therapy eligibility.
-
Integrate new treatment options into chronic disease management plans to enhance long-term asthma control and patient quality of life.
-
Many GPs have limited awareness of severe asthma phenotypes and the role of Type 2 inflammation in uncontrolled disease.
-
There is a knowledge gap in recognising patients who remain symptomatic despite optimised inhaler therapy.
-
GPs often need greater confidence in identifying candidates for biologic therapies and understanding referral criteria.
-
A need exists for improved collaboration with respiratory specialists to streamline patient assessment and management.
-
Enhancing GP skills in reviewing existing asthma patients and applying evidence-based care ensures alignment with current best-practice guidelines.
By completing this activity, participants will be able to:
-
Recognise the clinical features and diagnostic criteria of severe asthma and Type 2 inflammation.
-
Differentiate between mild-to-moderate asthma and cases that warrant escalation to advanced therapies.
-
Apply evidence-based assessment tools to identify patients not controlled on standard inhaled treatments.
-
Refer appropriately to local respiratory physicians for consideration of biologic therapy eligibility.
-
Integrate new treatment options into chronic disease management plans to enhance long-term asthma control and patient quality of life.
This activity is designed to help participants identify asthma patients who may require further treatment and specialist referral through practical, evidence-based learning.
Teaching methods include:
-
Specialist-led presentation explaining how to recognise patients with uncontrolled asthma despite optimal inhaled therapy.
-
Case-based discussions demonstrating when to escalate care and refer to a respiratory specialist for assessment and consideration of biologic therapy.
-
Interactive Q&A sessions to clarify clinical indicators, referral criteria, and local pathways.
AUS
can